• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症中表观遗传机制的失调。

Deregulation of epigenetic mechanisms in cancer.

作者信息

Maleszewska Marta, Wojtas Bartosz, Kamińska Bożena

机构信息

Instytut Biologii Doświadczalnej PAN im. M. Nenckiego w Warszawie.

出版信息

Postepy Biochem. 2018 Oct 15;64(2):148-156. doi: 10.18388/pb.2018_125.

DOI:10.18388/pb.2018_125
PMID:30656897
Abstract

Gene expression of both normal and cancer cell is tightly regulated by specific transcription regulators and epigenetic mechanisms such as DNA methylation, histone modifications (acetylation, methylation, phosphorylation), nucleosome remodeling and non-coding RNAs. Deregulation of epigenetic mechanisms plays a pivotal role in cancer, although researchers debate if it is a cause or a consequence of oncogenic transformation. Independently from the way in which epigenetic alterations arise in cancer, downstream effects will result in profound changes in transcriptomic and subsequently proteomic profiles. In most cases, changes in expression of epigenetic genes produce functional advantages in cell proliferation, tumor growth and/or migration capacity. Most of epigenetic changes in cancer are triggered by genomic alterations in specific genes that are involved in controlling one of the epigenetic mechanisms. However, there are also mutations in cell metabolism-related genes that affect activities of DNA demethylating enzymes and histone modifiers. Histone modifications are deregulated in cancer mostly due to alterations in genes coding for enzymes that attach or remove histone modifications. Mutations in genes coding for nucleosome remodelers result in aberrant global chromatin organization and facilitate subsequent global alterations of gene copy number or translocations. Recent advancements in next generation sequencing allowed for more precise mapping of global changes in the epigenetic landscape in cancer.

摘要

正常细胞和癌细胞的基因表达都受到特定转录调节因子和表观遗传机制的严格调控,这些机制包括DNA甲基化、组蛋白修饰(乙酰化、甲基化、磷酸化)、核小体重塑和非编码RNA。表观遗传机制的失调在癌症中起着关键作用,尽管研究人员对于它是致癌转化的原因还是结果存在争议。无论癌症中表观遗传改变是如何产生的,其下游效应都会导致转录组以及随后的蛋白质组图谱发生深刻变化。在大多数情况下,表观遗传基因表达的变化在细胞增殖、肿瘤生长和/或迁移能力方面产生功能优势。癌症中的大多数表观遗传变化是由参与控制一种表观遗传机制的特定基因的基因组改变引发的。然而,也存在与细胞代谢相关基因的突变,这些突变会影响DNA去甲基化酶和组蛋白修饰酶的活性。组蛋白修饰在癌症中失调主要是由于编码连接或去除组蛋白修饰的酶的基因发生改变。编码核小体重塑蛋白的基因突变会导致异常的全局染色质组织,并促进随后基因拷贝数的全局改变或易位。新一代测序技术的最新进展使得能够更精确地绘制癌症表观遗传景观的全局变化图谱。

相似文献

1
Deregulation of epigenetic mechanisms in cancer.癌症中表观遗传机制的失调。
Postepy Biochem. 2018 Oct 15;64(2):148-156. doi: 10.18388/pb.2018_125.
2
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.表观遗传药物作为癌症治疗中的多效性药物:生物分子方面及临床应用
J Cell Physiol. 2007 Aug;212(2):330-44. doi: 10.1002/jcp.21066.
3
Molecular Pathways: Metabolic Control of Histone Methylation and Gene Expression in Cancer.分子途径:癌症中组蛋白甲基化和基因表达的代谢调控
Clin Cancer Res. 2017 Aug 1;23(15):4004-4009. doi: 10.1158/1078-0432.CCR-16-2506. Epub 2017 Apr 12.
4
Interplay between different epigenetic modifications and mechanisms.不同表观遗传修饰和机制之间的相互作用。
Adv Genet. 2010;70:101-41. doi: 10.1016/B978-0-12-380866-0.60005-8.
5
Epigenetic alterations in cancer.癌症中的表观遗传改变。
Front Biosci (Landmark Ed). 2020 Mar 1;25(6):1058-1109. doi: 10.2741/4847.
6
The epigenetic breakdown of cancer cells: from DNA methylation to histone modifications.癌细胞的表观遗传破坏:从DNA甲基化到组蛋白修饰。
Prog Mol Subcell Biol. 2005;38:169-81. doi: 10.1007/3-540-27310-7_7.
7
Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications.胰腺癌中表观遗传调控因子的改变及其临床意义
Int J Mol Sci. 2016 Dec 19;17(12):2138. doi: 10.3390/ijms17122138.
8
Epigenetic gene regulation in cancer.癌症中的表观遗传基因调控
Adv Genet. 2008;61:247-67. doi: 10.1016/S0065-2660(07)00009-0.
9
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.表观遗传和染色质修饰剂作为血液系统恶性肿瘤的靶向治疗
J Clin Oncol. 2005 Jun 10;23(17):3971-93. doi: 10.1200/JCO.2005.16.600. Epub 2005 May 16.
10
Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.抑制DNA甲基化和组蛋白去乙酰化的表观遗传活性药物
Curr Pharm Des. 2017;23(8):1167-1174. doi: 10.2174/1381612822666161021110827.

引用本文的文献

1
Epigenetic dysregulation in cancer: mechanisms, diagnostic biomarkers and therapeutic strategies.癌症中的表观遗传失调:机制、诊断生物标志物及治疗策略
Med Oncol. 2025 Jul 21;42(8):359. doi: 10.1007/s12032-025-02905-z.
2
Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view.miRNAs 在多柔比星耐药中的调控作用:一种机制观点。
Funct Integr Genomics. 2024 Sep 2;24(5):150. doi: 10.1007/s10142-024-01431-x.
3
Comprehensive transcriptomic analyses identify KDM genes-related subtypes with different TME infiltrates in gastric cancer.
综合转录组分析确定胃癌中与不同 TME 浸润相关的 KDM 基因相关亚型。
BMC Cancer. 2023 May 18;23(1):454. doi: 10.1186/s12885-023-10923-1.
4
METTL3 promotes the malignancy of non-small cell lung cancer by N6-methyladenosine modifying SFRP2.METTL3 通过 N6-甲基腺苷修饰 SFRP2 促进非小细胞肺癌的恶性转化。
Cancer Gene Ther. 2023 Aug;30(8):1094-1104. doi: 10.1038/s41417-023-00614-1. Epub 2023 Apr 27.
5
Potential Therapeutics Targeting Upstream Regulators and Interactors of EHMT1/2.针对EHMT1/2上游调节因子和相互作用分子的潜在治疗方法。
Cancers (Basel). 2022 Jun 9;14(12):2855. doi: 10.3390/cancers14122855.
6
The Contrasting Delayed Effects of Transient Exposure of Colorectal Cancer Cells to Decitabine or Azacitidine.结直肠癌细胞短暂暴露于地西他滨或阿扎胞苷后的对比性延迟效应。
Cancers (Basel). 2022 Mar 16;14(6):1530. doi: 10.3390/cancers14061530.
7
The Emerging Significance of Histone Lysine Demethylases as Prognostic Markers and Therapeutic Targets in Head and Neck Cancers.组蛋白赖氨酸去甲基化酶作为头颈癌预后标志物和治疗靶点的新意义
Cells. 2022 Mar 17;11(6):1023. doi: 10.3390/cells11061023.
8
WHSC1 acts as a prognostic indicator and functions as an oncogene in cervical cancer.WHSC1作为一种预后指标,在宫颈癌中发挥癌基因的作用。
Onco Targets Ther. 2019 Jun 17;12:4683-4690. doi: 10.2147/OTT.S204701. eCollection 2019.